Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ACADIA Pharmaceuticals Inc.    ACAD

Delayed Quote. Delayed  - 10/21 10:00:00 pm
25.34 USD   +5.80%
10/11 ACADIA PHARMACE : Receives California Life Sciences Association&rsqu..
09/20 ACADIA PHARMACE : to Present at the Ladenburg Thalmann 2016 Healthca..
09/19 ACADIA PHARMACE : Sponsors National Parkinson Foundation’s Car..
News SummaryMost relevantAll newsSector news 

ACADIA Pharmaceuticals Inc. : & SUPERVALU Inc. Announcements: (NASDAQ: ACAD), (NYSE: SVU)

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2013 | 08:25am CEST

New York (March 22nd, 2013) - ACADIA Pharmaceuticals Inc.(NASDAQ: ACAD) announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results from ACADIA’s pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis at the Emerging Science session of the 65th American Academy of Neurology (AAN) Annual Meeting.

The analysis of the full data set from the Phase III -020 Study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top-line results previously reported.

“The significant and consistent results observed across measures in the Phase III -020 Study are impressive and potentially very encouraging for Parkinson’s patients who suffer from the psychosis frequently associated with this disease,” said Dr. Jeffrey Cummings.

Find out if this announcement could benefit ACAD in the very short term here:


SUPERVALU Inc. (NYSE: SVU) announced it completed the sale of its Albertsons, Acme, Jewel-Osco, Shaw’s and Star Market stores and related Osco and Sav-on in-store pharmacies to AB Acquisition LLC, an affiliate of a Cerberus Capital Management L.P.-led investor consortium, in a stock deal valued at $3.3 billion, including $100 million in cash and $3.2 billion in debt assumption.

Operations for these banners will transfer overnight, and the new SUPERVALU will open for business on Friday as a more efficient wholesale and retail company with annual sales of approximately $17 billion.

As part of the transaction, SUPERVALU also announced that Symphony Investors, a Cerberus-led investor consortium, completed its tender offer resulting in the acquisition of 11,686,406 shares (approximately 5.475 percent of SUPERVALU’s outstanding common stock) at a purchase price of $4.00 per share in cash.

Find out more on SVU here:


About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
10/11 ACADIA PHARMACEUTICALS : Receives California Life Sciences Association’s 2..
09/29 ACADIA PHARMACEUTICALS : Patent Issued for Methods for the Treatment of Parkinso..
09/20 ACADIA PHARMACEUTICALS : to Present at the Ladenburg Thalmann 2016 Healthcare Co..
09/19 ACADIA PHARMACEUTICALS : Sponsors National Parkinson Foundation’s Caregive..
09/14 ACADIA PHARMACEUTICALS : Biotech Stocks on Investors' Radar -- Eleven Biotherape..
09/06 ACADIA PHARMACEUTICALS : to Present at the Morgan Stanley Global Healthcare Conf..
08/24 ACADIA PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K..
08/24 ACADIA PHARMACEUTICALS : Announces Appointment of Todd S. Young as Executive Vic..
08/23 ACADIA PHARMACEUTICALS : Announces Full Exercise of Underwriters’ Option t..
08/11 ACADIA PHARMACEUTICALS : to Announce Second Quarter 2016 Financial Results on Au..
More news
Sector news : Biotechnology & Medical Research - NEC
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
10/20 Acadia Pharmaceuticals Seems To Have Just Gotten One Step Closer To Europe
10/14 Acadia Data In Alzheimer's And La Jolla's Acute Blood Pressure Project
10/13 2 Small Biotechs To Buy In This Week's Pullback
10/05 BIOTECH FORUM DAILY DIGEST : Follow Up On Progenics, Dynavax's Roller Coaster We..
10/05 Healthcare Regulatory Events And Data Releases To Watch In Q4
Financials ($)
Sales 2016 12,2 M
EBIT 2016 -244 M
Net income 2016 -241 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 249x
EV / Sales 2017 44,3x
Capitalization 3 034 M
More Financials
Duration : Period :
ACADIA Pharmaceuticals Inc Technical Analysis Chart | ACAD | US0042251084 | 4-Traders
Full-screen chart
Technical analysis trends ACADIA PHARMACEUT...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 42,8 $
Spread / Average Target 69%
Consensus details
EPS Revisions
More Estimates Revisions
Stephen R. Davis President, Chief Executive Officer & Director
Stephen R. Biggar Chairman
James A. Nash Vice President-Technology Development & Operations
Todd S. Young EVP, Chief Financial & Accounting Officer
James Owen Chief Medical Officer & SVP-Clinical Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 863
LONZA GROUP AG13.92%9 846
ALKERMES PLC-29.93%8 430
More Results